FDAFinal Rule
Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies
HealthcareTechnology
Ad Space (leaderboard)
Summary
The FDA is establishing official safety and effectiveness standards for a laboratory test that detects chromosomal abnormalities in blood cancer patients. This classification helps ensure that hospitals and diagnostic labs use reliable, high-quality tests to help doctors diagnose and treat blood cancers more accurately.
Key Points
- 1The FDA is classifying a specific genetic test (FISH-based detection) used to identify chromosome problems in patients with blood cancers like leukemia and lymphoma
- 2This classification sets quality and performance standards that laboratories must meet before offering this test to patients
- 3The test helps doctors diagnose blood cancers more quickly and accurately by detecting abnormal chromosomes that indicate cancer
- 4Clinical laboratories and hospitals that perform this test will need to follow FDA requirements to ensure their results are reliable and trustworthy
- 5This regulation improves patient safety by making sure cancer diagnostic tests meet consistent national standards
Impact Assessment
If you are a diagnostic laboratory or hospital, this means you must ensure your fluorescence in situ hybridization tests meet FDA safety and effectiveness standards for detecting blood cancer chromosomal abnormalities.
Impact Level
Moderate
Geographic Scope
National
Compliance Cost
Moderate
Who is Affected
Healthcare ProvidersManufacturersSmall Businesses
Key Dates
Published
June 26, 2025
Regulatory Connections
Authorized By
Amends CFR Sections
21 CFR Part 86021 CFR Part 864
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.
The Digest Network
Ad Space (rectangle)